Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1058 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Not yet recruiting Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer
Condition: Bronchial Cancer
Intervention: Device: With and without SDB
4 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
5 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
6 Not yet recruiting Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab;   Other: Durvalumab plus SBRT
7 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
8 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
9 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
10 Not yet recruiting A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Locally Advanced Squamous Non-Small Cell Lung Cancer;   Metastatic Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Necitumumab;   Drug: Gemcitabine;   Drug: Carboplatin
11 Not yet recruiting Anti PD-1 Neo-adjuvant Treatment for NSCLC
Conditions: Non Small Cell Lung Carcinoma;   Stage I;   Stage II
Interventions: Drug: Pembrolizumab 200 mg IV single dose;   Drug: Pembrolizumab 200 mg IV twice interval 21 days;   Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d;   Drug: Pembrolizumab 100 mg I.V single dose;   Procedure: Surgical resection of tumor
12 Not yet recruiting 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Condition: Non-small-cell Lung Cancer
Intervention: Radiation: 18F-FDG
13 Not yet recruiting A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Condition: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Interventions: Drug: Durvalumab and Tremelimumab;   Drug: AZD1775 and carboplatin (CBPT)
14 Not yet recruiting Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Carcinoma;   Small Cell Lung Carcinoma
Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage;   Other: Laboratory Biomarker Analysis
15 Not yet recruiting PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Conditions: Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
Intervention: Drug: PEN-221
16 Not yet recruiting A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Conditions: Advanced Solid Tumors;   Non-Small Cell Lung Carcinoma (NSCLC);   Triple Negative Breast Cancer (TNBC);   Endometrial Cancer;   Anaplastic Thyroid Cancer
Interventions: Drug: FAZ053;   Drug: PDR001
17 Not yet recruiting Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer (SCLC)
Interventions: Biological: Pembrolizumab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiation therapy
18 Recruiting TR(ACE) Assay Clinical Specimen Study
Conditions: Carcinoma, Non-Small-Cell Lung;   Breast Neoplasms
Intervention: Device: TR(ACE) Assay Testing
19 Recruiting Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program
Conditions: Non-small Cell Lung Cancer;   Nivolumab;   Long-term Adverse Effects
20 Not yet recruiting Gefitinib Long-term Survivor Study
Condition: EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years